192725-17-0

• 常用中文名：洛匹那韦
• 常用英文名：Lopinavir
• CAS号：192725-17-0
• 分子式：C₃₇H₄₈N₄O₅
• 分子量：628.801
• 相关类别： 原料药 人工合成抗感染类药 抗病毒类药
• 发布时间：2018-07-07 14:29:31
• 更新时间：2026-06-30 20:08:20
• Lopinavir是高亲和性HIV蛋白酶抑制剂,Ki为1.3 pM。

名称

• 中文名: 洛匹那韦
• 英文名: lopinavir
• 中文别名: 洛匹那韦,10 MM DMSO 溶液; 洛匹那韦检测标准品; 洛比那韦; Lopinavir 10mg试剂; 匹洛那韦; 洛匹那韦峰鉴别 标准品; 洛匹那韦 LOPINAVIR; 洛匹那韦192-0; Lopinavir (ABT-378) 洛匹那韦，S1380; 罗平拉韦; 洛匹那韦系统适用性 标准品; (2S)-N-[(2R,4S,5S)-5-[[2-(2,6-二甲基苯氧基)乙酰]氨基]-4-羟基-1,6-二苯基-己-2-基]-3-甲基-2-(2-氧代-1,3-二氮杂环己-1-基)丁酰胺; Lopinavir (ABT-378) 10mM * 1mL in DMSO试剂; 洛吡那韦; 洛匹那韦 Solbio/索莱宝 IL0820; (S)-N-((2S,4S,5S)-5-(2-(2,6-二甲基苯氧基)乙酰胺基)-4-羟基-1,6-二苯基己-2-基)-3-甲基-2-(2-氧代四氢嘧啶-1(2H)-基)丁酰胺; 洛匹那韦(对照品); 洛匹那韦, HIV 蛋白酶抑制剂; Lopinavir (ABT-378) 洛匹那韦,S1380; N-((2S,4S,5S)-5-(2-(2,6-二甲基苯氧基)乙酰胺基)-4-羟基-1,6-二苯基己-2-基)-3-甲基-2-(2-氧代四氢嘧啶-1(2H)-基)丁酰胺; 洛匹那韦 标准品; 乙腈中洛匹那韦; Lopinavir 试剂; 洛匹那韦(标准品)
• 英文别名: (2S)-N-[(2S,4S,5S)-5-[2-(2,6-diMethylphenoxy)acetaMido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-Methyl-2-(2-oxo-1,3-diazinan-1-yl)butanaMide; (S)-N-((2S,4S,5S)-5-(2-(2,6-dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenylhexan-2-yl)-3-methyl-2-(2-oxo-tetrahydropyrimidin-1(2H)-yl)butanamide; Lopinavir, 10 mM in DMSO; LopinavirQ: What is Lopinavir Q: What is the CAS Number of Lopinavir Q: What is the storage condition of Lopinavir; (2S)-N-[(2S,4S,5S)-5-{[(2,6-Dimethylphenoxy)acetyl]amino}-4-hydroxy-1,6-diphenyl-2-hexanyl]-3-methyl-2-(2-oxotetrahydro-1(2H)-pyrimidinyl)butanamide; (2S)-N-[(1S,3S,4S)-1-benzyl-4-{[(2,6-diméthylphénoxy)acétyl]amino}-3-hydroxy-5-phénylpentyl]-3-méthyl-2-(2-oxotétrahydropyrimidin-1(2H)-yl)butanamide; ABT 378; (2s)-n-[(2r,4s,5s)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenyl-hexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide; Lopinavir for peak identification; Lopinavir HIV protease inhibitor; Lopinavir for peak identification CRS; LOPINAVIR; Aluvia); (aS)-Tetrahydro-N-((aS)-a-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-a-isopropyl-2-oxo-1(2H)-pyrimidineacetamide; Lopinavir - Bio-X; (2S)-N-[(2S,4S,5S)-5-{[(2,6-Dimethylphenoxy)acetyl]amino}-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide; ABT 378/r; (aS)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-α-(1-methylethyl)-2-oxo-1(2H)-Pyrimidineacetamide; Lopinavir for system suitability CRS; 1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-α-(1-methylethyl)-2-oxo-, (αS); MFCD04973616; Lopinavir //BP; (S)-N-((2R,4S,5S)-5-(2-(2,6-Dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenyl-hexn-2-yl)-3-met; Lopinavir RS; Lopinavir CRS; Lopinavir for system suitability; (2S)-N-[(1S,3S,4S)-1-Benzyl-4-{[(2,6-dimethylphenoxy)acetyl]amino}-3-hydroxy-5-phenylpentyl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamid; Aluviran; LOPINAVIR [DRUG SUBSTANCE (NON-STERILE)]; (αS)-N-[(1S,3S,4S)-4-[[2-(2,6-DiMethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylMethyl)pentyl]tetrahydro-α-(1-Methylethyl)-2-oxo-1(2H)-pyriMidineacetaMide; Lopinavir (ABT-378); Koletr; Lopinavir in Acetonitrile; (2S)-N-[(1S,3S,4S)-1-benzyl-4-{[(2,6-dimethylphenoxy)acetyl]amino}-3-hydroxy-5-phenylpentyl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide; (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenyl-hexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide; ABT-378 whatsapp; Koletra; LOPINAVIR (NON STERILE DRUG SUBSTANCE); (S)-N-((2R,4S,5S)-5-(2-(2,6-Dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenyl-hexn-2-yl)-3-methyl; Lopinavir (LPV); (aS)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-a-(1-methylethyl)-2-oxo-1(2H)-Pyrimidineacetamide; N-((2S,4S,5S)-5-(2-(2,6-DiMethylphenoxy)acetaMido)-4-hydroxy-1,6-diphenylhexan-2-yl)-3-Methyl-2-(2-oxotetrahydropyriMidin-1(2H)-yl)butanaMide; Lopinavir White to off-white powder

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 924.2±65.0 °C at 760 mmHg
• 熔点: 124-127°C
• 分子式: C₃₇H₄₈N₄O₅
• 分子量: 628.801
• 闪点: 512.7±34.3 °C
• 精确质量: 628.362488
• PSA: 120.00000
• LogP: 6.26
• 外观性状: 白色结晶固体
• 蒸汽压: 0.0±0.3 mmHg at 25°C
• 折射率: 1.577
• 储存条件: Hygroscopic, -20°C Freezer, Under inert atmosphere
• 稳定性: Hygroscopic
• 水溶解性: 水溶性：不溶；可溶于：甲醇,乙醇
• 分子结构:

  1、 摩尔折射率：179.07

  2、 摩尔体积（cm³/mol）：541.0

  3、 等张比容（90.2K）：1433.3

  4、 表面张力（dyne/cm）：49.2

  5、 极化率（10-24cm3）：70.99

• 更多:

  1.性状：结晶固体

  2.熔点（ºC）：124～127

生物活性

• 描述: Lopinavir是高亲和性HIV蛋白酶抑制剂,Ki为1.3 pM。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> HIV蛋白酶
  信号通路 >> 抗感染 >> HIV
  研究领域 >> 炎症/免疫
• 参考文献:

  [1]. Vishnuvardhan, D., et al., Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS, 2003. 17(7): p. 1092-4.

  [2]. Gonzalez, L.M., et al., In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother, 2003. 47(9): p. 2817-22.

  [3]. Weemhoff, J.L., et al., Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol, 2003. 55(3): p. 381-6.

  [4]. Sham, H.L., et al., ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother, 1998. 42(12): p. 3218-24.

安全

• 危害码 (欧洲): Xi
• 危险品运输编码: NONH for all modes of transport

合成路线

上下游产品

上游产品  8
192725-49-8 192725-50-1 192800-77-4 72-18-4
126147-70-4 144163-85-9 156732-15-9 162849-93-6
下游产品  0

制备

在一定温度下，向二甲亚砜和二氯甲烷的溶液中滴加草酰氯。反应后，加入犖苄氧基羰基氨基丙醇的二氯甲烷溶液，反应一段时间后，滴加三乙胺，搅拌。将其放入冷的10%柠檬酸水溶液中，用乙醚提取。有机层合并，饱和盐水洗涤、干燥、过滤、减压浓缩。经硅胶层析提纯得氨基丙醛衍生物。将其溶于甲醇，加入缬氨酸甲醇盐酸盐、乙酸钠和氰氢硼化钠，在室温搅拌，减压浓缩后溶于乙酸乙酯，用饱和碳酸氢钠洗，洗液用乙酸乙酯提取。有机层合并，用饱和盐水洗，干燥，过滤，减压浓缩。得到的物质用硅胶层析提纯，得缩合还原产物。将该产物进行加氢，然后和等摩尔的1,1-羰基二(1-四氢-嘧啶)在二氯甲烷中反应。所得产物在水和二氧六环中，用氢氧化锂进行水解，盐酸酸化后用乙酸乙酯提取。提取液经干燥、过滤、减压浓缩，得2S-(四氢嘧啶-2-氧-1-基)-3-甲基丁酸。将其和(2S,3S,5S)-2-(2,6-二甲基苯氧乙酰基)氨基-3-羟基-5-氨基-1,6-二苯己烷溶于二甲基甲酰胺，加入1-(3-二甲氨基丙基)-3-乙基碳化二亚胺，反应即得罗匹那韦。